-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Q&A with Jamie E. Chaft, MD, Regarding the ALCHEMIST Platform
Posted: December 2017 How do you envision immunotherapy interdigitating in the adjuvant and neoadjuvant setting in resectable nonsmall cell lung cancer (NSCLC)? PACIFIC, which demonstrated a marked progression-free survival (PFS) advantage of 1 year of durvalumab after definitive concurrent chemoradiation in patients with unresectable NSCLC, gives us hope that this class of agents may likewise…
-
Utility and Controversies Surrounding Use of New Techniques in Radiotherapy
By Suresh Senan, MRCP, FRCR, PhD Posted: December 2017 Improved delivery of radiotherapy has contributed to the recent changes in guidelines for patients with lung cancer. The clinical impact of some technical advances has been modest, but the cumulative effect of many developments has led to more precise treatment delivery, and has increased the confidence…
-
IASLC WCLC 2017 Presidential Symposium Presents Leading Lung Cancer Research
By Cynthia L. Kryder, MS Posted: December 2017 The IASLC WCLC 2017 Presidential Symposium in Yokohama, Japan, recognized the authors of 3 exceptional lung cancer research abstracts. Patient-reported Outcomes from the PACIFIC Trial According to previously reported efficacy and safety results of the PACIFIC trial, patients with locally advanced stage III NSCLC receiving durvalumab post…
-
National Cancer Institute Adds Latest Clinical Trial to the ALCHEMIST Platform
By Cynthia L. Kryder, MSPosted: December 2017 Despite genomic advances in the treatment of advanced lung cancer over the past decade, few breakthroughs have emerged in the adjuvant treatment of patients with resected non-small cell lung cancer (NSCLC) in whom there is a 50% chance that the cancer will recur after standard treatment. Consequently, the…
-
Evolution in Treatment of Brain Metastases in Mutation-Driven Non-Small Cell Lung Cancer
By Jason K. Molitoris, MD, PhD, Anthony D. Nehlsen, MD, and Minesh P. Mehta, MD Posted: October 2017 Up to 40% of patients with advanced non-small cell lung cancer (NSCLC) will develop brain metastases (BM); this contributes significantly to decrement in survival and quality of life. Optimal BM treatment in patients with targetable rearrangements in…
-
New Strategy for Tobacco Regulation
By Erik J. MacLaren, PhD Posted: October 2017 On July 28, 2017, the U.S. Food and Drug Administration (FDA) announced a new, multi-year strategy intended to reduce tobacco-related disease and mortality. As part of this new strategy, the agency will begin developing a plan to reduce nicotine in combustible cigarettes to non-addictive levels and delay…
-
Role of Allied Health Professionals in the Multidisciplinary Lung Cancer Team
By Carol Brimacombe, State Registered Occupational Therapist (SROT) Posted: October 2017 The emerging role of allied health professionals in the multidisciplinary thoracic cancer team (MDT) is only just being acknowledged by the wider oncology community. How best to define and integrate their role into disease management remains a challenge. In the United Kingdom (UK), patients…
-
Exploring the Potential of Immuno-oncology Combination Therapy
By Cynthia L. Kryder, MS, CCC-Sp Posted: October 2017 Editor Note: The article is part of a newly launched ongoing series about immunooncology (IO) combination therapy, future articles of which will address PD-L1 and CTLA-4 combinations as well as IO in a curative setting, the Blueprint project, managing toxicities, as well as other related topics.…
-
Proton-Beam Therapy Versus Photon-Beam Therapy: The Debate Continues
By Cynthia L. Kryder, MS, CCC-Sp Posted: October 2017 For patients who present with inoperable, locally advanced lung cancer, photon-based chemoradiation remains the standard of care. Despite advanced radiation-delivery techniques, such as multi-leaf collimators, intensity-modulated radiotherapy (IMRT), and imageguided radiotherapy (IGRT), radiation oncologists continue to explore ways to extend the ALARA principle, that is, the…
-
Q & A with Yi-Long Wu, MD
What is the current standard of care in the adjuvant setting post-resection of high-risk NSCLC in your practice or nationally?Posted: October 2017 Current Chinese Lung Cancer Diagnosis and Treatment Guideline from the Chinese Society of Clinical Oncology (CSCO) recommends adjuvant platinum- based doublet chemotherapy as the standard of care (SOC) for completely resected stage II-III…